Top news of the week: 04.05.2022.
Companies And Industries
Cancer Immunotherapy Developers in Asia Explore Diverse Approaches
Novel concepts include intra-cellular-antigen-binding antibodies, light-activated drugs, antiviral T cells, and PD-1-based DNA vaccines.
Is Biogen Planning to Appeal CMS Aduhelm Reimbursement Decision?
Speculations that Biogen might appeal the decision after reports of the company hiring several lobbyists, including Clyburn Consulting and Federal Street Strategies.
How to Land a Biotech Job, According to Experts
We sat down with Associate Director of Talent Acquisition Jennifer Metivier and Chief People Officer Jennifer Peterson of Obsidian Therapeutics to discuss what type of candidates they ...
Google, Sanofi back UK biotech OMass’ $100m second round
UK biotech OMass raises a sizeable $100m in Series B led by new investors Google Northpond and Sanofi Ventures, as it moves candidates against 'undruggable' targets towards the clinic
FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine
FDA Announces Vaccines and Related Biological Products Advisory Committee Review of Novavax' COVID-19 Vaccine - read this article along with other careers information, tips and advice on ...
Good Day BIO: China's regulations could restrict access and use of human genetic resources by foreign entities
China's proposed human genetic resources regulation may significantly impact global R&D efforts coordinated by foreign entities—here’s why it matters and what BIO’s doing about it. ...
A company developing a human blood substitute attempts a comeback, but IPO plans look dicey
Biopure, the disgraced developer of a failed human blood substitute, is attempting a comeback.
China Introduces Strict New Bioethics Guidelines for Genetics Materials
China's proposed guidelines for bioethics say that organizations outside of China cannot collect and preserve Chinese human genetic resources inside China or take them out of the country.